ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
vrs37
|
210 |
115K |
0 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
210
|
115K
|
0
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
vrs37
|
210 |
115K |
0 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
210
|
115K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
vrs37
|
176 |
55K |
2 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
176
|
55K
|
2
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
vrs37
|
210 |
115K |
4 |
05/02/24 |
05/02/24 |
ASX - By Stock
|
210
|
115K
|
4
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
vrs37
|
210 |
115K |
1 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
210
|
115K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
vrs37
|
58 |
16K |
3 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
58
|
16K
|
3
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
vrs37
|
210 |
115K |
1 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
210
|
115K
|
1
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
vrs37
|
210 |
115K |
2 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
210
|
115K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
vrs37
|
58 |
16K |
1 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
58
|
16K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
vrs37
|
59 |
20K |
3 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
59
|
20K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
vrs37
|
59 |
20K |
1 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
59
|
20K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
vrs37
|
58 |
16K |
6 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
58
|
16K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
vrs37
|
59 |
20K |
1 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
59
|
20K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
vrs37
|
59 |
20K |
0 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
59
|
20K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US
|
|
vrs37
|
21 |
8.2K |
0 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
21
|
8.2K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: AGM Presentation
|
|
vrs37
|
77 |
26K |
2 |
05/01/24 |
05/01/24 |
ASX - By Stock
|
77
|
26K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: AGM Presentation
|
|
vrs37
|
77 |
26K |
3 |
03/01/24 |
03/01/24 |
ASX - By Stock
|
77
|
26K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: AGM Presentation
|
|
vrs37
|
77 |
26K |
1 |
02/01/24 |
02/01/24 |
ASX - By Stock
|
77
|
26K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: AGM Presentation
|
|
vrs37
|
77 |
26K |
8 |
02/01/24 |
02/01/24 |
ASX - By Stock
|
77
|
26K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix (ASX: DXB) Discussion Thread
|
|
vrs37
|
640 |
224K |
8 |
31/12/23 |
31/12/23 |
ASX - By Stock
|
640
|
224K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix (ASX: DXB) Discussion Thread
|
|
vrs37
|
640 |
224K |
5 |
27/12/23 |
27/12/23 |
ASX - By Stock
|
640
|
224K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First USA site initiated in aGvHD trial
|
|
vrs37
|
31 |
8.5K |
2 |
27/12/23 |
27/12/23 |
ASX - By Stock
|
31
|
8.5K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
67K |
3 |
11/12/23 |
11/12/23 |
ASX - By Stock
|
231
|
67K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
67K |
5 |
09/12/23 |
09/12/23 |
ASX - By Stock
|
231
|
67K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
67K |
3 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
231
|
67K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
67K |
1 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
231
|
67K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
News: ATX Amplia Therapeutics Says Approval From Korean Regulator
|
|
vrs37
|
13 |
5.2K |
3 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
13
|
5.2K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
67K |
4 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
231
|
67K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
67K |
4 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
231
|
67K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
67K |
2 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
231
|
67K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
News: ATX Amplia Therapeutics Says Approval From Korean Regulator
|
|
vrs37
|
13 |
5.2K |
3 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
13
|
5.2K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
67K |
0 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
231
|
67K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
67K |
1 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
231
|
67K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
67K |
3 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
231
|
67K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: mRNA Vaccine Enhancer Shows Inflammation Reduction
|
|
vrs37
|
45 |
20K |
1 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
45
|
20K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: AGM Presentation
|
|
vrs37
|
77 |
26K |
8 |
22/11/23 |
22/11/23 |
ASX - By Stock
|
77
|
26K
|
8
|
|
ASX - By Stock
|
NOX |
Re:
Ann: mRNA Vaccine Enhancer Shows Inflammation Reduction
|
|
vrs37
|
45 |
20K |
0 |
22/11/23 |
22/11/23 |
ASX - By Stock
|
45
|
20K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Announces License Agreement for EU, Canada, ANZ
|
|
vrs37
|
423 |
152K |
3 |
20/11/23 |
20/11/23 |
ASX - By Stock
|
423
|
152K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Announces License Agreement for EU, Canada, ANZ
|
|
vrs37
|
423 |
152K |
1 |
18/11/23 |
18/11/23 |
ASX - By Stock
|
423
|
152K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Announces License Agreement for EU, Canada, ANZ
|
|
vrs37
|
423 |
152K |
3 |
17/11/23 |
17/11/23 |
ASX - By Stock
|
423
|
152K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
|
|
vrs37
|
26 |
9.1K |
2 |
16/11/23 |
16/11/23 |
ASX - By Stock
|
26
|
9.1K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: AACR Pancreatic Cancer Conference Presentation
|
|
vrs37
|
2 |
1.1K |
1 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
2
|
1.1K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Receives Initial Upfront Payment from Advanz Pharma
|
|
vrs37
|
155 |
41K |
4 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
155
|
41K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Receives Initial Upfront Payment from Advanz Pharma
|
|
vrs37
|
155 |
41K |
6 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
155
|
41K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Receives Initial Upfront Payment from Advanz Pharma
|
|
vrs37
|
155 |
41K |
7 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
155
|
41K
|
7
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
|
|
vrs37
|
26 |
9.1K |
5 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
26
|
9.1K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
|
|
vrs37
|
26 |
9.1K |
7 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
26
|
9.1K
|
7
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
vrs37
|
16 |
11K |
3 |
07/11/21 |
07/11/21 |
ASX - By Stock
|
16
|
11K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
vrs37
|
16 |
11K |
2 |
03/11/21 |
03/11/21 |
ASX - By Stock
|
16
|
11K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
vrs37
|
16 |
11K |
3 |
02/11/21 |
02/11/21 |
ASX - By Stock
|
16
|
11K
|
3
|
|